Compare OOMA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | ARVN |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.1M | 600.2M |
| IPO Year | 2015 | 2018 |
| Metric | OOMA | ARVN |
|---|---|---|
| Price | $19.16 | $7.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 15 |
| Target Price | ★ $26.80 | $14.46 |
| AVG Volume (30 Days) | 285.0K | ★ 768.5K |
| Earning Date | 12-07-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | 58.84 |
| EPS | 0.20 | ★ 0.88 |
| Revenue | $114,490,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $21.68 | $5.49 |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | $94.28 | ★ $4.12 |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $6.74 |
| 52 Week High | $26.19 | $14.22 |
| Indicator | OOMA | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 41.00 |
| Support Level | $16.42 | $6.74 |
| Resistance Level | $19.56 | $7.77 |
| Average True Range (ATR) | 0.67 | 0.41 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 5.36 | 24.19 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.